Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend

Abstract

IntroductionWe explored the relationship between early deep remission and rates of dosage adjustment for patients (pts) with Crohn's disease (CD).MethodsEXTEND studied the effects of adalimumab (ADA) on mucosal healing in...